Eric F. Johnson, Ph.D. - Publications

Affiliations: 
Department of Molecular Medicine Scripps Research Institute, La Jolla, La Jolla, CA, United States 
 1972 Chemistry University of Illinois, Urbana-Champaign, Urbana-Champaign, IL 
Website:
https://www.scripps.edu/research/faculty/ejohnson

75 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Savas U, Wei S, Hsu MH, Falck JR, Guengerich FP, Capdevila JH, Johnson EF. 20-Hydroxyeicosatetraenoic Acid (HETE) Dependent Hypertension in Human Cytochrome P450 (CYP) 4A11 Transgenic Mice: Normalization of Blood Pressure by Sodium Restriction, Hydrochlorothiazide, or Blockade of the Type 1 Angiotensin II Receptor. The Journal of Biological Chemistry. PMID 27298316 DOI: 10.1074/jbc.M116.732297  1
2015 Brodney MA, Beck EM, Butler CR, Barreiro G, Johnson EF, Riddell D, Parris K, Nolan CE, Fan Y, Atchison K, Gonzales C, Robshaw AE, Doran SD, Bundesmann MW, Buzon L, et al. Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors. Journal of Medicinal Chemistry. 58: 3223-52. PMID 25781223 DOI: 10.1021/acs.jmedchem.5b00191  1
2015 Wang A, Stout CD, Zhang Q, Johnson EF. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding. The Journal of Biological Chemistry. 290: 5092-104. PMID 25555909 DOI: 10.1074/jbc.M114.627661  1
2014 Johnson EF, Connick JP, Reed JR, Backes WL, Desai MC, Xu L, Estrada DF, Laurence JS, Scott EE. Correlating structure and function of drug-metabolizing enzymes: Progress and ongoing challenges Drug Metabolism and Disposition. 42: 9-22. PMID 24130370 DOI: 10.1124/dmd.113.054627  1
2013 Tong Y, Stewart KD, Florjancic AS, Harlan JE, Merta PJ, Przytulinska M, Soni N, Swinger KK, Zhu H, Johnson EF, Shoemaker AR, Penning TD. Azaindole-Based Inhibitors of Cdc7 Kinase: Impact of the Pre-DFG Residue, Val 195. Acs Medicinal Chemistry Letters. 4: 211-5. PMID 24900653 DOI: 10.1021/ml300348c  1
2013 Johnson EF, Stout CD. Structural diversity of eukaryotic membrane cytochrome p450s. The Journal of Biological Chemistry. 288: 17082-90. PMID 23632020 DOI: 10.1074/jbc.R113.452805  1
2012 Reynald RL, Sansen S, Stout CD, Johnson EF. Structural characterization of human cytochrome P450 2C19: Active site differences between P450s 2C8, 2C9, and 2C19 Journal of Biological Chemistry. 287: 44581-44591. PMID 23118231 DOI: 10.1074/jbc.M112.424895  1
2012 Zhang Q, Xia Z, Mitten MJ, Lasko LM, Klinghofer V, Bouska J, Johnson EF, Penning TD, Luo Y, Giranda VL, Shoemaker AR, Stewart KD, Djuric SW, Vasudevan A. Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors Bioorganic and Medicinal Chemistry Letters. 22: 7615-7622. PMID 23103095 DOI: 10.1016/j.bmcl.2012.10.009  1
2012 Susanti D, Johnson EF, Rodriguez JR, Anderson I, Perevalova AA, Kyrpides N, Lucas S, Han J, Lapidus A, Cheng JF, Goodwin L, Pitluck S, Mavrommatis K, Peters L, Land ML, et al. Complete genome sequence of Desulfurococcus fermentans, a hyperthermophilic cellulolytic crenarchaeon isolated from a freshwater hot spring in Kamchatka, Russia. Journal of Bacteriology. 194: 5703-4. PMID 23012283 DOI: 10.1128/JB.01314-12  1
2012 Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. The Journal of Pharmacology and Experimental Therapeutics. 343: 617-27. PMID 22935731 DOI: 10.1124/jpet.112.197087  1
2012 Zhu GD, Gong J, Gandhi VB, Liu X, Shi Y, Johnson EF, Donawho CK, Ellis PA, Bouska JJ, Osterling DJ, Olson AM, Park C, Luo Y, Shoemaker A, Giranda VL, et al. Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer. Bioorganic & Medicinal Chemistry. 20: 4635-45. PMID 22766219 DOI: 10.1016/j.bmc.2012.06.021  1
2012 Wang A, Savas U, Hsu MH, Stout CD, Johnson EF. Crystal structure of human cytochrome P450 2D6 with prinomastat bound. The Journal of Biological Chemistry. 287: 10834-43. PMID 22308038 DOI: 10.1074/jbc.M111.307918  1
2012 Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Ladror US, Xu AJ, Iyer R, Harlan JE, Solomon LR, Donawho CK, ... ... Johnson EF, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 510-23. PMID 22128301 DOI: 10.1158/1078-0432.CCR-11-1973  1
2011 Bumpus NN, Johnson EF. 5-Aminoimidazole-4-carboxyamide-ribonucleoside (AICAR)-stimulated hepatic expression of Cyp4a10, Cyp4a14, Cyp4a31, and other peroxisome proliferator-activated receptor α-responsive mouse genes is AICAR 5'-monophosphate-dependent and AMP-activated protein kinase-independent. The Journal of Pharmacology and Experimental Therapeutics. 339: 886-95. PMID 21896918 DOI: 10.1124/jpet.111.184242  1
2011 Shi Y, Solomon LR, Pereda-Lopez A, Giranda VL, Luo Y, Johnson EF, Shoemaker AR, Leverson J, Liu X. Ubiquitin-specific cysteine protease 2a (USP2a) regulates the stability of Aurora-A. The Journal of Biological Chemistry. 286: 38960-8. PMID 21890637 DOI: 10.1074/jbc.M111.231498  1
2011 Hsu MH, Savas U, Lasker JM, Johnson EF. Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway. The Journal of Pharmacology and Experimental Therapeutics. 337: 125-36. PMID 21205922 DOI: 10.1124/jpet.110.175851  1
2011 Wang A, Savas U, Stout CD, Johnson EF. Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1. The Journal of Biological Chemistry. 286: 5736-43. PMID 21147782 DOI: 10.1074/jbc.M110.204420  1
2010 Wang GT, Mantei RA, Hubbard RD, Wilsbacher JL, Zhang Q, Tucker L, Hu X, Kovar P, Johnson EF, Osterling DJ, Bouska J, Wang J, Davidsen SK, Bell RL, Sheppard GS. Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases. Bioorganic & Medicinal Chemistry Letters. 20: 6067-71. PMID 20817523 DOI: 10.1016/j.bmcl.2010.08.052  1
2010 Hu G, Johnson EF, Kemper B. CYP2C8 exists as a dimer in natural membranes Drug Metabolism and Disposition. 38: 1976-1983. PMID 20699412 DOI: 10.1124/dmd.110.034942  1
2010 Fidanze SD, Erickson SA, Wang GT, Mantei R, Clark RF, Sorensen BK, Bamaung NY, Kovar P, Johnson EF, Swinger KK, Stewart KD, Zhang Q, Tucker LA, Pappano WN, Wilsbacher JL, et al. Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 20: 2452-5. PMID 20346655 DOI: 10.1016/j.bmcl.2010.03.015  1
2010 Penning TD, Zhu GD, Gong J, Thomas S, Gandhi VB, Liu X, Shi Y, Klinghofer V, Johnson EF, Park CH, Fry EH, Donawho CK, Frost DJ, Buchanan FG, Bukofzer GT, et al. Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor. Journal of Medicinal Chemistry. 53: 3142-53. PMID 20337371 DOI: 10.1021/jm901775y  1
2010 Gandhi VB, Luo Y, Liu X, Shi Y, Klinghofer V, Johnson EF, Park C, Giranda VL, Penning TD, Zhu GD. Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorganic & Medicinal Chemistry Letters. 20: 1023-6. PMID 20045315 DOI: 10.1016/j.bmcl.2009.12.042  1
2010 Annalora AJ, Goodin DB, Hong WX, Zhang Q, Johnson EF, Stout CD. Crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism. Journal of Molecular Biology. 396: 441-51. PMID 19961857 DOI: 10.1016/j.jmb.2009.11.057  1
2010 Harris CM, Ericsson AM, Argiriadi MA, Barberis C, Borhani DW, Burchat A, Calderwood DJ, Cunha GA, Dixon RW, Frank KE, Johnson EF, Kamens J, Kwak S, Li B, Mullen KD, et al. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization. Bioorganic & Medicinal Chemistry Letters. 20: 334-7. PMID 19926477 DOI: 10.1016/j.bmcl.2009.10.103  1
2009 Tong Y, Bouska JJ, Ellis PA, Johnson EF, Leverson J, Liu X, Marcotte PA, Olson AM, Osterling DJ, Przytulinska M, Rodriguez LE, Shi Y, Soni N, Stavropoulos J, Thomas S, et al. Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents. Journal of Medicinal Chemistry. 52: 6803-13. PMID 19888760 DOI: 10.1021/jm900697r  1
2009 Tao ZF, Hasvold LA, Leverson JD, Han EK, Guan R, Johnson EF, Stoll VS, Stewart KD, Stamper G, Soni N, Bouska JJ, Luo Y, Sowin TJ, Lin NH, Giranda VS, et al. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. Journal of Medicinal Chemistry. 52: 6621-36. PMID 19842661 DOI: 10.1021/jm900943h  1
2009 Liu X, Han EK, Anderson M, Shi Y, Semizarov D, Wang G, McGonigal T, Roberts L, Lasko L, Palma J, Zhu GD, Penning T, Rosenberg S, Giranda VL, Luo Y, ... ... Johnson EF, et al. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Molecular Cancer Research : McR. 7: 1686-92. PMID 19825992 DOI: 10.1158/1541-7786.MCR-09-0299  1
2009 Pappano WN, Jung PM, Meulbroek JA, Wang YC, Hubbard RD, Zhang Q, Grudzien MM, Soni NB, Johnson EF, Sheppard GS, Donawho C, Buchanan FG, Davidsen SK, Bell RL, Wang J. Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605. Bmc Cancer. 9: 314. PMID 19732452 DOI: 10.1186/1471-2407-9-314  1
2009 Miyashiro J, Woods KW, Park CH, Liu X, Shi Y, Johnson EF, Bouska JJ, Olson AM, Luo Y, Fry EH, Giranda VL, Penning TD. Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorganic & Medicinal Chemistry Letters. 19: 4050-4. PMID 19553114 DOI: 10.1016/j.bmcl.2009.06.016  1
2009 Savas U, Machemer DE, Hsu MH, Gaynor P, Lasker JM, Tukey RH, Johnson EF. Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model. The Journal of Biological Chemistry. 284: 16541-52. PMID 19366684 DOI: 10.1074/jbc.M902074200  1
2009 Hubbard RD, Bamaung NY, Fidanze SD, Erickson SA, Palazzo F, Wilsbacher JL, Zhang Q, Tucker LA, Hu X, Kovar P, Osterling DJ, Johnson EF, Bouska J, Wang J, Davidsen SK, et al. Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 19: 1718-21. PMID 19217287 DOI: 10.1016/j.bmcl.2009.01.086  1
2009 Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, Klinghofer V, Johnson EF, Donawho CK, Frost DJ, Bontcheva-Diaz V, Bouska JJ, Osterling DJ, Olson AM, Marsh KC, et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. Journal of Medicinal Chemistry. 52: 514-23. PMID 19143569 DOI: 10.1021/jm801171j  1
2008 Palma JP, Rodriguez LE, Bontcheva-Diaz VD, Bouska JJ, Bukofzer G, Colon-Lopez M, Guan R, Jarvis K, Johnson EF, Klinghofer V, Liu X, Olson A, Saltarelli MJ, Shi Y, Stavropoulos JA, et al. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Research. 28: 2625-35. PMID 19035287  1
2008 Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, Zhu GD, Johnson EF, Rodriguez LE, Ghoreishi-Haack N, Jarvis K, Hradil VP, Colon-Lopez M, Cox BF, Klinghofer V, et al. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks Molecular Cancer Research. 6: 1621-1629. PMID 18922977 DOI: 10.1158/1541-7786.MCR-08-0240  1
2008 Tong Y, Stewart KD, Thomas S, Przytulinska M, Johnson EF, Klinghofer V, Leverson J, McCall O, Soni NB, Luo Y, Lin NH, Sowin TJ, Giranda VL, Penning TD. Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling. Bioorganic & Medicinal Chemistry Letters. 18: 5206-8. PMID 18790640 DOI: 10.1016/j.bmcl.2008.08.079  1
2008 Kartha JS, Skordos KW, Sun H, Hall C, Easterwood LM, Reilly CA, Johnson EF, Yost GS. Single mutations change CYP2F3 from a dehydrogenase of 3-methylindole to an oxygenase. Biochemistry. 47: 9756-70. PMID 18717595 DOI: 10.1021/bi8005658  1
2008 Mast N, White MA, Bjorkhem I, Johnson EF, Stout CD, Pikuleva IA. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proceedings of the National Academy of Sciences of the United States of America. 105: 9546-51. PMID 18621681 DOI: 10.1073/pnas.0803717105  1
2008 Zhu GD, Gandhi VB, Gong J, Thomas S, Luo Y, Liu X, Shi Y, Klinghofer V, Johnson EF, Frost D, Donawho C, Jarvis K, Bouska J, Marsh KC, Rosenberg SH, et al. Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent. Bioorganic & Medicinal Chemistry Letters. 18: 3955-8. PMID 18586490 DOI: 10.1016/j.bmcl.2008.06.023  1
2008 Penning TD, Zhu GD, Gandhi VB, Gong J, Thomas S, Lubisch W, Grandel R, Wernet W, Park CH, Fry EH, Liu X, Shi Y, Klinghofer V, Johnson EF, Donawho CK, et al. Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorganic & Medicinal Chemistry. 16: 6965-75. PMID 18541433 DOI: 10.1016/j.bmc.2008.05.044  1
2008 White MA, Mast N, Bjorkhem I, Johnson EF, Stout CD, Pikuleva IA. Use of complementary cation and anion heavy-atom salt derivatives to solve the structure of cytochrome P450 46A1. Acta Crystallographica. Section D, Biological Crystallography. 64: 487-95. PMID 18453684 DOI: 10.1107/S0907444908004046  1
2008 Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Research. 68: 3421-8. PMID 18451170 DOI: 10.1158/0008-5472.CAN-07-5836  1
2008 Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF. Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. The Journal of Biological Chemistry. 283: 17227-37. PMID 18413310 DOI: 10.1074/jbc.M802180200  1
2008 Gracias V, Ji Z, Akritopoulou-Zanze I, Abad-Zapatero C, Huth JR, Song D, Hajduk PJ, Johnson EF, Glaser KB, Marcotte PA, Pease L, Soni NB, Stewart KD, Davidsen SK, Michaelides MR, et al. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors Bioorganic and Medicinal Chemistry Letters. 18: 2691-2695. PMID 18362070 DOI: 10.1016/j.bmcl.2008.03.021  1
2007 Hubbard RD, Bamaung NY, Palazzo F, Zhang Q, Kovar P, Osterling DJ, Hu X, Wilsbacher JL, Johnson EF, Bouska J, Wang J, Bell RL, Davidsen SK, Sheppard GS. Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR). Bioorganic & Medicinal Chemistry Letters. 17: 5406-9. PMID 17689078 DOI: 10.1016/j.bmcl.2007.07.037  1
2007 Johnson EF, Stewart KD, Woods KW, Giranda VL, Luo Y. Pharmacological and functional comparison of the polo-like kinase family: Insight into inhibitor and substrate specificity Biochemistry. 46: 9551-9563. PMID 17655330 DOI: 10.1021/bi7008745  1
2007 Sansen S, Hsu MH, Stout CD, Johnson EF. Structural insight into the altered substrate specificity of human cytochrome P450 2A6 mutants. Archives of Biochemistry and Biophysics. 464: 197-206. PMID 17540336 DOI: 10.1016/j.abb.2007.04.028  1
2007 Zhu GD, Gandhi VB, Gong J, Thomas S, Woods KW, Song X, Li T, Diebold RB, Luo Y, Liu X, Guan R, Klinghofer V, Johnson EF, Bouska J, Olson A, et al. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. Journal of Medicinal Chemistry. 50: 2990-3003. PMID 17523610 DOI: 10.1021/jm0701019  1
2007 Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, ... ... Johnson EF, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2728-37. PMID 17473206 DOI: 10.1158/1078-0432.CCR-06-3039  1
2007 Dinges J, Albert DH, Arnold LD, Ashworth KL, Akritopoulou-Zanze I, Bousquet PF, Bouska JJ, Cunha GA, Davidsen SK, Diaz GJ, Djuric SW, Gasiecki AF, Gintant GA, Gracias VJ, Harris CM, ... ... Johnson EF, et al. 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel. Journal of Medicinal Chemistry. 50: 2011-29. PMID 17425296 DOI: 10.1021/jm061223o  1
2007 Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD, Johnson EF. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. The Journal of Biological Chemistry. 282: 14348-55. PMID 17311915 DOI: 10.1074/jbc.M611692200  1
2007 Zhu GD, Gong J, Gandhi VB, Woods K, Luo Y, Liu X, Guan R, Klinghofer V, Johnson EF, Stoll VS, Mamo M, Li Q, Rosenberg SH, Giranda VL. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt. Bioorganic & Medicinal Chemistry. 15: 2441-52. PMID 17258463 DOI: 10.1016/j.bmc.2007.01.010  1
2007 Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, Osterling DJ, Guo J, Marcotte PA, Johnson EF, Soni N, Hartandi K, et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood. 109: 3400-8. PMID 17209055 DOI: 10.1182/blood-2006-06-029579  1
2006 Yano JK, Denton TT, Cerny MA, Zhang X, Johnson EF, Cashman JR. Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. Journal of Medicinal Chemistry. 49: 6987-7001. PMID 17125252 DOI: 10.1021/jm060519r  1
2006 Woods KW, Fischer JP, Claiborne A, Li T, Thomas SA, Zhu GD, Diebold RB, Liu X, Shi Y, Klinghofer V, Han EK, Guan R, Magnone SR, Johnson EF, Bouska JJ, et al. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors. Bioorganic & Medicinal Chemistry. 14: 6832-46. PMID 16843670 DOI: 10.1016/j.bmc.2006.06.047  1
2006 Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ, Haasch DL, Wang S, Clampit JE, Johnson EF, Lubben TH, et al. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. Journal of Medicinal Chemistry. 49: 3563-80. PMID 16759099 DOI: 10.1021/jm060199b  1
2006 Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, Wang B, Bukofzer GT, Wang YC, Stavropoulos JA, Hartandi K, ... ... Johnson EF, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics. 5: 995-1006. PMID 16648571 DOI: 10.1158/1535-7163.MCT-05-0410  1
2006 Zhu GD, Gandhi VB, Gong J, Luo Y, Liu X, Shi Y, Guan R, Magnone SR, Klinghofer V, Johnson EF, Bouska J, Shoemaker A, Oleksijew A, Jarvis K, Park C, et al. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers. Bioorganic & Medicinal Chemistry Letters. 16: 3424-9. PMID 16644221 DOI: 10.1016/j.bmcl.2006.04.005  1
2006 Zhu GD, Gong J, Claiborne A, Woods KW, Gandhi VB, Thomas S, Luo Y, Liu X, Shi Y, Guan R, Magnone SR, Klinghofer V, Johnson EF, Bouska J, Shoemaker A, et al. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity. Bioorganic & Medicinal Chemistry Letters. 16: 3150-5. PMID 16603355 DOI: 10.1016/j.bmcl.2006.03.041  1
2006 Li Q, Woods KW, Thomas S, Zhu GD, Packard G, Fisher J, Li T, Gong J, Dinges J, Song X, Abrams J, Luo Y, Johnson EF, Shi Y, Liu X, et al. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer. Bioorganic & Medicinal Chemistry Letters. 16: 2000-7. PMID 16413780 DOI: 10.1016/j.bmcl.2005.12.065  1
2006 Li Q, Li T, Zhu GD, Gong J, Claibone A, Dalton C, Luo Y, Johnson EF, Shi Y, Liu X, Klinghofer V, Bauch JL, Marsh KC, Bouska JJ, Arries S, et al. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioorganic & Medicinal Chemistry Letters. 16: 1679-85. PMID 16403626 DOI: 10.1016/j.bmcl.2005.12.017  1
2005 Johnson EF, Stout CD. Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases. Biochemical and Biophysical Research Communications. 338: 331-6. PMID 16157296 DOI: 10.1016/j.bbrc.2005.08.190  1
2005 Yano JK, Hsu MH, Griffin KJ, Stout CD, Johnson EF. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nature Structural & Molecular Biology. 12: 822-3. PMID 16086027 DOI: 10.1038/nsmb971  1
2005 Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, Han EK, Li T, Stoll VS, Powlas JA, Oleksijew A, Mitten MJ, Shi Y, Guan R, McGonigal TP, ... ... Johnson EF, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Molecular Cancer Therapeutics. 4: 977-86. PMID 15956255 DOI: 10.1158/1535-7163.MCT-05-0005  1
2004 Melet A, Marques-Soares C, Schoch GA, Macherey AC, Jaouen M, Dansette PM, Sari MA, Johnson EF, Mansuy D. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants Biochemistry. 43: 15379-15392. PMID 15581350 DOI: 10.1021/bi0489309  1
2004 Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. The Journal of Biological Chemistry. 279: 38091-4. PMID 15258162 DOI: 10.1074/jbc.C400293200  1
2004 Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, Johnson EF. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. The Journal of Biological Chemistry. 279: 35630-7. PMID 15181000 DOI: 10.1074/jbc.M405427200  1
2004 Scott EE, White MA, He YA, Johnson EF, Stout CD, Halpert JR. Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-A resolution: insight into the range of P450 conformations and the coordination of redox partner binding. The Journal of Biological Chemistry. 279: 27294-301. PMID 15100217 DOI: 10.1074/jbc.M403349200  1
2004 Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. The Journal of Biological Chemistry. 279: 9497-503. PMID 14676196 DOI: 10.1074/jbc.M312516200  1
2003 Scott EE, He YA, Wester MR, White MA, Chin CC, Halpert JR, Johnson EF, Stout CD. An open conformation of mammalian cytochrome P450 2B4 at 1.6-A resolution. Proceedings of the National Academy of Sciences of the United States of America. 100: 13196-201. PMID 14563924 DOI: 10.1073/pnas.2133986100  1
2003 Liu F, Johnson EF, Austin DJ, Anderson KS. Adenosine-anchored triphosphate subsite probing: distinguishing between HER-2 and HER-4 tyrosine protein kinases. Bioorganic & Medicinal Chemistry Letters. 13: 3587-92. PMID 14505676 DOI: 10.1016/S0960-894X(03)00761-3  1
2003 Wester MR, Johnson EF, Marques-Soares C, Dijols S, Dansette PM, Mansuy D, Stout CD. Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 Å resolution: Evidence for an induced fit model of substrate binding Biochemistry. 42: 9335-9345. PMID 12899620 DOI: 10.1021/bi034556l  1
2003 Wester MR, Johnson EF, Marques-Soares C, Dansette PM, Mansuy D, Stout CD. Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 Å resolution: Evidence for multiple substrate binding modes Biochemistry. 42: 6370-6379. PMID 12767218 DOI: 10.1021/bi0273922  1
2003 Marques-Soares C, Dijols S, Macherey AC, Wester MR, Johnson EF, Dansette PM, Mansuy D. Sulfaphenazole derivatives as tools for comparing cytochrome P450 2C5 and human cytochromes P450 2Cs: Identification of a new high affinity substrate common to those enzymes Biochemistry. 42: 6363-6369. PMID 12767217 DOI: 10.1021/bi027391+  1
2003 Atreya CE, Johnson EF, Irwin JJ, Dow A, Massimine KM, Coppens I, Stempliuk V, Beverley S, Joiner KA, Shoichet BK, Anderson KS. A molecular docking strategy identifies Eosin B as a non-active site inhibitor of protozoal bifunctional thymidylate synthase-dihydrofolate reductase. The Journal of Biological Chemistry. 278: 14092-100. PMID 12556445 DOI: 10.1074/jbc.M212690200  1
2002 Johnson EF, Wester MR, Stout CD. The structure of microsomal cytochrome P450 2C5: a steroid and drug metabolizing enzyme. Endocrine Research. 28: 435-41. PMID 12530646  1
Show low-probability matches.